

Somerset Pharmaceuticals Incorporated

[View the current Somerset Pharmaceuticals Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biorporate/9654-Somerset+Pharmaceuticals+Incorporated.html)

(<http://www.bioportfolio.com/biorporate/9654-Somerset+Pharmaceuticals+Incorporated.html>)

Contact Details:

Tel: 813 288 0040

Fax:

Email:

FL

United States of America

Recent Publications by Somerset Pharmaceuticals Incorporated:



- [Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system \(6 mg/24 h\): a comparison with oral selegiline capsules.](#)
*The selegiline transdermal system is a monoamine oxidase inhibitor that...*8th December, 2007
Somerset Pharmaceuticals- J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. ([DOI Direct Link](#))
- [Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents \(pseudoephedrine and phenylpropranolamine\) in healthy volunteers.](#)
*Selegiline transdermal system is a recently approved monoamine oxidase...*29th September, 2007
Somerset Pharmaceuticals, Inc.- J Clin Pharmacol. 2007 Aug;47(8):978-90. Epub 2007 Jun 6. ([DOI Direct Link](#))
- [Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.](#)
*BACKGROUND: Monoamine oxidase inhibitors are well recognized as effective...*3rd May, 2007
Somerset Pharmaceuticals, Tampa, FL 33607, USA.- CNS Spectr. 2007 Jan;12(1):25-34.
- [Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications.](#)
*Selegiline transdermal system (STS) is a recently approved monoamine...*14th April, 2007
Chief Scientific Officer, Somerset Pharmaceuticals, Inc, Rocky Point- J Clin Pharmacol. 2007 Feb;47(2):146-58. ([DOI Direct Link](#))
- [Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in](#)

[healthy subjects.](#)

*The oral tyramine pressor test was administered to healthy males during...*9th December, 2006
Somerset Pharmaceuticals, Inc, Tampa, Florida, USA.- J Clin Pharmacol. 2006 Aug;46(8):933-44. ([DOI Direct Link](#))

• [Tyramine pharmacokinetics and reduced bioavailability with food.](#)

*Tyramine challenge studies have demonstrated that it requires...*10th September, 2003
Somerset Pharmaceuticals, Inc., Tampa, Florida, USA.- J Clin Pharmacol. 2003 Jun;43(6):604-9.

• [Pharmacokinetics and Safety of a Selegiline Transdermal System Relative to Single-Dose Oral Administration in the Elderly.](#)

*This open-label, two-phase cross-over study compared the safety and...*28th February, 2002
Somerset Pharmaceuticals, Tampa, FL, USA.- Am J Ther. 1996 Oct;3(10):688-698.

• [Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.](#)

*Selegiline is a selective, irreversible inhibitor of MAO-B, used in the...*20th June, 2000
Somerset Pharmaceuticals, Tampa, FL-33607, USA.- Biopharm Drug Dispos. 1997 Nov;18(8):665-80.

• [Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.](#)

*Selegiline (SEL) is a selective, irreversible inhibitor of MAO-B, used in...*20th June, 2000
Somerset Pharmaceuticals, Tampa, FL 33607, USA.- Biopharm Drug Dispos. 1997 Oct;18(7):567-84.

• [Toxicokinetic evaluation of a selegiline transdermal system in the dog.](#)

*The toxicology and toxicokinetics of a selegiline transdermal system (STS)...*20th June, 2000
Somerset- Biopharm Drug Dispos. 1997 Mar;18(2):165-84.

Press Releases on Somerset Pharmaceuticals Incorporated:

Accuray Incorporated to Present at Piper Jaffray Healthcare Conference and J. P. Morgan Small/Mid Cap Conference	23rd November, 2009	Accuray Incorporated	<i>SUNNYVALE, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its management is scheduled to present at</i>
Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter	23rd November, 2009	Transcept Pharmaceuticals, Inc.	<i>POINT RICHMOND, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA)</i>
NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options	23rd November, 2009	National Comprehensive Cancer Network	<i>Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra(TM), GlaxoSmithKline) as a therapy</i>

[Poniard Announces \\$7.4 Million Financing](#) 23rd November, 2009 Poniard Pharmaceuticals

SAN FRANCISCO, Nov. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals (Nasdaq: PARD) today announced the sale of 3,465,878 of its common shares to Azimuth Opportunity Ltd. for gross proceeds of

[Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman](#) 23rd November, 2009 Ligon Discovery, Inc.

CAMBRIDGE, Mass., Nov. 23 /PRNewswire/ -- Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced the appointment

BioNews Results for Somerset Pharmaceuticals Incorporated



- [FDA Approves New Salix Product Exclusively in Catalent s Zydis Fast Dissolve Technology](#)
SmartBrief: Nov 4 2009 8:13AM Matching: somerset pharmaceuticals
- [FDA Approves New Salix Product Exclusively in Catalent's Zydis Fast Dissolve Technology](#)
Pharmacy Choice: Nov 3 2009 11:14PM Matching: somerset pharmaceuticals
- [Catalent Receives Outsourcing Award](#)
SmartBrief: Oct 20 2009 10:40PM Matching: somerset pharmaceuticals
- [Catalent Receives Outsourcing Award](#)
Business Wire via Yahoo!: Oct 20 2009 2:22PM Matching: somerset pharmaceuticals
- [Catalent Receives Outsourcing Award](#)
NewsBlaze: Oct 20 2009 5:21PM Matching: somerset pharmaceuticals
- [Meda Launches Onsolis\(TM\) \(Fentanyl Buccal Soluble Film\) for the Treatment of Breakthrough Cancer Pain in Opio](#)
Healthcare Sales & Marketing Network: Oct 16 2009 12:09AM Matching: somerset pharmaceuticals
- [Meda Launches Onsolis\(TM\) \(Fentanyl Buccal Soluble Film\) for the Treatment of Breakthrough Cancer Pain in Opio](#)
Pharmacy Choice: Oct 14 2009 2:38AM Matching: somerset pharmaceuticals
- [MEDA Launches Onsolis\(TM\) \(Fentanyl Buccal Soluble Film\) for the Treatment of Breakthrough Cancer Pain in Opio](#)
BioSpace: Oct 14 2009 12:15AM Matching: somerset pharmaceuticals
- [Meda Launches Onsolis\(TM\) \(Fentanyl Buccal Soluble Film\) for the Treatment of Breakthrough Cancer Pain in Opio](#)
PR Newswire via Yahoo!: Oct 13 2009 12:48PM Matching: somerset pharmaceuticals
- [Meda Launches Onsolis\(TM\) \(Fentanyl Buccal Soluble Film\) for the Treatment of Breakthrough Cancer Pain in Opio](#)
PR Newswire: Oct 13 2009 5:37PM Matching: somerset pharmaceuticals
- [Meda Launches Onsolis\(TM\) \(Fentanyl Buccal Soluble Film\) for the Treatment of Breakthrough Cancer Pain in Opio](#)

NewsBlaze: Oct 13 2009 12:10PM Matching: somerset pharmaceuticals

- [Meda Launches Onsolis\(TM\) \(Fentanyl Buccal Soluble Film\) for the Treatment of Breakthrough Cancer Pain in Opioid Tolerant Patients](#)

Individual.com: Oct 13 2009 12:15PM Matching: somerset pharmaceuticals

- [Meda Launches Onsolis\(TM\) \(Fentanyl Buccal Soluble Film\) for the Treatment of Breakthrough Cancer Pain in Opioid Tolerant Patients](#)

Individual.com: Oct 13 2009 12:15PM Matching: somerset pharmaceuticals

- [Meda Launches Onsolis\(TM\) \(Fentanyl Buccal Soluble Film\) for the Treatment of Breakthrough Cancer Pain in Opioid Tolerant Patients](#)

Individual.com: Oct 13 2009 12:14PM Matching: somerset pharmaceuticals

- [Meda Receives FDA Approval of New Astepro \(azelastine HCl\) Nasal Spray 0.15%, the First and Only Once-Daily Na](#)

Pharma Live: Sep 2 2009 1:06PM Matching: somerset pharmaceuticals

Somerset Pharmaceuticals Incorporated Clinical Trials:



- [PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly](#)

Somerset Pharmaceuticals Incorporated Patents:



- 7147864- [Methods for preventing photodamaged skin by administering selegiline or desmethylselegiline](#)
- 6420433- [S\(+\) desmethylselegiline and drug withdrawal](#)
- 6419948- [R\(-\)desmethylselegiline and its use in transdermal delivery compositions](#)
- 6375979- [S\(+\) desmethylselegiline and its use in transdermal delivery compositions](#)
- 6348208- [Methods and pharmaceutical compositions employing desmethylselegiline](#)
- 6319954- [S-\(+\)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions](#)
- 6299901- [Methods and pharmaceutical compositions employing desmethylselegiline](#)
- 6239181- [Method for preventing and treating peripheral neuropathy by administering selegiline](#)
- 6210706- [S \(+\) Desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions](#)
- 6117912- [Sublingual and buccal administration of selegiline for treating certain selegiline-responsive diseases and conditions](#)
- 6033682- [S\(+\) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions](#)
- 6455060- [S\(+\) desmethylselegiline and its use to treat immune system dysfunction](#)
- 6461619- [Method for treating wounds, burns and dermatological damage by administering selegiline or](#)

[desmethylselegiline](#)

- 7144584- [S\(+\)](#) [desmethylselegiline and its use to treat narcolepsy](#)
- 6759053- [S\(+\)](#) [Desmethylselegiline and its use to treat ADHD](#)
- 6743824- [Method for preventing and treating peripheral neuropathy by administering selegiline](#)
- 6709664- [Methods for treating photodamaged skin by administering selegiline or desmethylselegiline](#)
- 6699495- [Methods for treating multiple sclerosis employing desmethylselegiline](#)
- 6562365- [Methods employing R\(-\)-desmethylselegiline](#)
- 6562364- [Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms](#)
- 6538036- [Method for preventing and treating peripheral neuropathy by administering selegiline](#)
- 6528082- [Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions](#)
- 6500868- [Method for preventing and treating peripheral neuropathy by administering selegiline](#)
- 5242950- [Treatment of macular degeneration](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

